Monitoring of safety and effectiveness of cladribine in multiple sclerosis patients over 50 years

被引：11

作者：

Disanto, Giulio ^{[1
]}

Moccia, Marcello ^{[2
]}

Sacco, Rosaria ^{[1
]}

Spiezia, Antonio Luca ^{[2
]}

Carotenuto, Antonio ^{[2
]}

Morra, Vincenzo Brescia ^{[2
]}

Gobbi, Claudio ^{[1
,3
]}

Zecca, Chiara ^{[1
,3
]}

机构：

[1] EOC, Multiple Sclerosis Ctr, Dept Neurol, Neuroctr Southern Switzerland, Lugano, Switzerland

[2] Univ Naples Federico II, Dept Neurosci, Multiple Sclerosis Clin Care & Res Unit, Naples, Italy

[3] Univ Svizzera Italiana, Fac Biomed Sci, Lugano, Switzerland

来源：

MULTIPLE SCLEROSIS AND RELATED DISORDERS | 2022年 / 58卷

关键词：

Cladribine; Age; Safety; Lymphocyte counts; ORAL CLADRIBINE;

D O I：

10.1016/j.msard.2022.103490

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Clinical trial data regarding efficacy and safety of cladribine in MS are limited to young individuals, and the overall risk-benefit profile does not necessarily applies to elderly patients. We investigated effectiveness and safety outcomes in MS patients initiating cladribine at >= 50 years (n=35) and < 50 years (n=62), over a median follow-up of 12.4 months. There were no differences in time to evidence of disease activity (HR=0.73, 95% CI=0.18-2.91, p=0.657), post-treatment lymphocyte counts (beta=0.24, p=0.825) or occurrence of adverse events (OR=0.84, 95%CI=0.24-2.93, p=0.791) between age groups. Female sex and greater disability were associated with higher risk of adverse events (especially infections). These limited data do not suggest safety concerns regarding use of cladribine in elderly MS.

引用

页数：3

共 9 条

[1] Leveraging real-world data to investigate multiple sclerosis disease behavior, prognosis, and treatment [J].

Cohen, Jeffrey A. ;

Trojano, Maria ;

Mowry, Ellen M. ;

Uitdehaag, Bernard M. J. ;

Reingold, Stephen C. ;

Marrie, Ruth Ann .

MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (01) :23-37

[2]

Coyle PK, 2021, ACTRIMS FORUM

[3]

Giovannoni G, 2018, ECTRIMS

[4] Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis [J].

Giovannoni, Gavin ;

Cook, Stuart ;

Rammohan, Kottil ;

Rieckmann, Peter ;

Sorensen, Per Soelberg ;

Vermersch, Patrick ;

Hamlett, Anthony ;

Viglietta, Vissia ;

Greenberg, Steven .

LANCET NEUROLOGY, 2011, 10 (04) :329-337

[5] A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis [J].

Giovannoni, Gavin ;

Comi, Giancarlo ;

Cook, Stuart ;

Rammohan, Kottil ;

Rieckmann, Peter ;

Sorensen, Per Soelberg ;

Vermersch, Patrick ;

Chang, Peter ;

Hamlett, Anthony ;

Musch, Bruno ;

Greenberg, Steven J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (05) :416-426

[6] Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial [J].

Leist, Thomas P. ;

Comi, Giancarlo ;

Cree, Bruce A. C. ;

Coyle, Patricia K. ;

Freedman, Mark S. ;

Hartung, Hans-Peter ;

Vermersch, Patrick ;

Casset-Semanaz, Florence ;

Scaramozza, Matthew .

LANCET NEUROLOGY, 2014, 13 (03) :257-267

[7] Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria [J].

Thompson, Alan J. ;

Banwell, Brenda L. ;

Barkhof, Frederik ;

Carroll, William M. ;

Coetzee, Timothy ;

Comi, Giancarlo ;

Correale, Jorge ;

Fazekas, Franz ;

Filippi, Massimo ;

Freedman, Mark S. ;

Fujihara, Kazuo ;

Galetta, Steven L. ;

Hartung, Hans Peter ;

Kappos, Ludwig ;

Lublin, Fred D. ;

Marrie, Ruth Ann ;

Miller, Aaron E. ;

Miller, David H. ;

Montalban, Xavier ;

Mowry, Ellen M. ;

Sorensen, Per Soelberg ;

Tintore, Mar ;

Traboulsee, Anthony L. ;

Trojano, Maria ;

Uitdehaag, Bernard M. J. ;

Vukusic, Sandra ;

Waubant, Emmanuelle ;

Weinshenker, Brian G. ;

Reingold, Stephen C. ;

Cohen, Jeffrey A. .

LANCET NEUROLOGY, 2018, 17 (02) :162-173

[8] Efficacy of cladribine tablets in high disease activity patients with relapsing multiple sclerosis: post hoc analysis of subgroups with and without prior disease-modifying drug treatment [J].

Vermersch, Patrick ;

Galazka, Andrew ;

Dangond, Fernando ;

Damian, Doris ;

Wong, Schiffon L. ;

Jack, Dominic ;

Harty, Gerard .

CURRENT MEDICAL RESEARCH AND OPINION, 2021, 37 (03) :459-464

[9] Impact of Age on Multiple Sclerosis Disease Activity and Progression [J].

Zeydan, Burcu ;

Kantarci, Orhun H. .

CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS, 2020, 20 (07)

← 1 →